ImmunoGen, Inc. is a biotechnology firm currently in the clinical development phase, specializing in the creation of antibody-drug conjugates (ADCs) designed for cancer treatment. Among its pipeline, mirvetuximab soravtansine is a prominent ADC, presently undergoing Phase III clinical trials, aimed at platinum-resistant ovarian cancer by targeting folate-receptor alpha (FRa). Another key candidate, Pivekimab sunirine, an ADC designed to target CD123, is progressing through Phase II trials for the management of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.